Short description: Iodinated I-125 human serum albumin
Iodine (125I) human albumin| Clinical data |
|---|
| Trade names | Jeanatope |
|---|
| AHFS/Drugs.com | FDA Professional Drug Information |
|---|
Routes of administration | Intravenous injection |
|---|
| ATC code | |
|---|
| Legal status |
|---|
| Legal status |
|
|---|
| Pharmacokinetic data |
|---|
| Elimination half-life | ~14 days |
|---|
| Excretion | via kidneys |
|---|
| Identifiers |
|---|
| PubChem SID | |
|---|
| DrugBank | |
|---|
| UNII | |
|---|
| KEGG | |
|---|
Iodine (125I) human albumin (trade name Jeanatope) is human serum albumin iodinated with iodine-125, typically injected to aid in the determination of total blood and plasma volume.[1][2]
Iodine-131 iodinated albumin (trade name Volumex) is used for the same purposes.[3]
Medical uses
Iodine (125I) human albumin is used to determine a person's blood volume. For this purpose, a defined amount of radioactivity in form of this drug is injected into a vein, and blood samples are drawn from a different body location after five and fifteen minutes. From the radioactivity of these samples, the original radioactivity per blood volume can be calculated; and knowing the total amount of radioactivity injected, one can calculate the total blood volume.[1]
It can also be used to calculate the blood plasma volume using a similar method. The main difference is that the drawn blood sample has to be centrifuged to separate the plasma from the blood cells.[1]
Contraindications
The US Food and Drug Administration lists no contraindications for this drug.[1]
Adverse effects
There is a theoretical possibility of allergic reactions after repeated use of this medication.[1]
Pharmacokinetics
Iodine-125 is a radioactive isotope of iodine that decays by electron capture with a physical half-life of 60.14 days. The biological half-life in normal individuals for iodine (125I) human albumin has been reported to be approximately 14 days. Its radioactivity is excreted almost exclusively via the kidneys.[1]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Jeanatope FDA Professional Drug Information. Accessed 21 April 2021.
- ↑ DrugBank DB09429
. Accessed 21 April 2021.
- ↑ Volumex Injection FDA Professional Drug Information. Accessed 21 April 2021.
Diagnostic radiopharmaceuticals (ATC: V09) |
|---|
| Central nervous system |
- 99mTc (Exametazime)
- 123I (Ioflupane
- Iofetamine
- Iomazenil)
- 18F (Florbetapir, Flutemetamol)
|
|---|
| Skeletal system | |
|---|
| Renal |
- 123I (Sodium iodohippurate)
- 64Cu (Cu-ETS2)
|
|---|
| Gastrointestinal/Hepatic | |
|---|
| Respiratory system |
- 133Xe
- 81mKr
- 99mTc (99mTc-MAA)
|
|---|
| Cardiovascular system |
- 99mTc (Sestamibi
- Tetrofosmin)
- 111In (Imciromab)
- 82Rb (Rubidium chloride)
|
|---|
| Inflammation/infection |
- 99mTc (Exametazime
- Sulesomab
- Tilmanocept)
- 111In
- 67Ga
|
|---|
| Tumor |
- 99mTc (Arcitumomab
- Votumumab
- Hynic-octreotide)
- 111In (Capromab pendetide
- Satumomab pendetide)
- 125I (Minretumomab)
- 123I / 131I (Iobenguane)
- 18F (Fluciclovine
- Fludeoxyglucose
- Fluoroethyltyrosine
- Sodium fluoride)
|
|---|
| Adrenal cortex |
- 123I
- 125I / 131I (Iodocholesterol)
|
|---|
Radionuclides (including tracers) | | positron (PET list) |
- 11C ([11C]ME@HAPTHI
- 25B-NBOMe (Cimbi-36)
- Acetate
- Choline
- Carfentanil
- DASB
- DTBZ
- Flumazenil
- Methionine
- N-Methylspiperone
- Pittsburgh compound B
- Raclopride
- Verapamil)
- 13N (Ammonia)
- 15O (Water)
- 18F (Altanserin
- Desmethoxyfallypride
- FMISO
- Fallypride
- Florbetaben
- Florbetapir
- Flubatine
- Fluciclovine
- Fludeoxyglucose (18F) (FDG)-glucose analogue
- Flumazenil
- Fluorocholine
- Fluorodeoxysorbitol (FDS)
- Fluorodopa
- Fluorothymidine F-18
- Fluspidine
- Flutemetamol
- MPPF
- Mefway
- Nifene
- N-Methylspiperone
- FET
- Setoperone)
- 64Cu
- 68Ga
- 82Rb (Rubidium chloride)
|
|---|
| gamma ray/photon (SPECT/scintigraphy) |
- 51Cr
- 57Co
- 67Ga
- 75Se
- 81mKr
- 99mTc
- 111In
- 123I
- 125I
- 131I
- 133Xe
- 153Sm
- 201Tl
|
|---|
|
|---|
 | Original source: https://en.wikipedia.org/wiki/Iodine (125I) human albumin. Read more |